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Summary
Background: The	pathogenesis	of	infant	colic	is	poorly	defined.	Gut	microbiota	seems	
to	be	involved,	supporting	the	potential	therapeutic	role	of	probiotics.
Aims: To	assess	the	rate	of	infants	with	a	reduction	of	≥50%	of	mean	daily	crying	du‐
ration	after	28	days	of	intervention	with	the	probiotic	Bifidobacterium animalis	subsp.	
lactis	BB‐12®	 (BB‐12).	Secondary	outcomes	were	daily	number	of	crying	episodes,	
sleeping	time,	number	of	bowel	movements	and	stool	consistency.
Methods: Randomized	controlled	trial	(RCT)	on	otherwise	healthy	exclusively	breast‐
fed	infants	with	infant	colic	randomly	allocated	to	receive	BB‐12	(1	×	109	CFU/day)	or	
placebo	for	28	days.	Gut	microbiota	structure	and	butyrate,	beta‐defensin‐2	(HBD‐2),	
cathelicidin	(LL‐37),	secretory	IgA	(sIgA)	and	faecal	calprotectin	levels	were	assessed.
Results: Eighty	infants	were	randomised,	40/group.	The	rate	of	infants	with	reduction	of	
≥50%	of	mean	daily	crying	duration	was	higher	in	infants	treated	with	BB‐12,	start‐
ing	from	the	end	of	2nd	week.	No	infant	relapsed	when	treatment	was	stopped.	The	
mean	number	of	crying	episodes	decreased	in	both	groups,	but	with	a	higher	effect	
in	BB‐12	group	(−4.7	±	3.4	vs	−2.3	±	2.2,	P	<	0.05).	Mean	daily	stool	frequency	de‐
creased	 in	both	groups	but	the	effect	was	significantly	higher	 in	the	BB‐12	group;	
stool	consistency	was	similar	between	the	two	groups.	An	increase	in	Bifidobacterium 
abundance	 (with	 significant	 correlation	 with	 crying	 time	 reduction),	 butyrate	 and	
HBD‐2,	LL‐37,	sIgA	levels	associated	with	a	decrease	in	faecal	calprotectin	level	were	
observed	in	the	BB‐12	group.
Conclusions: Supplementation	with	BB‐12	is	effective	in	managing	infant	colic.	The	
effect	 could	 derive	 from	 immune	 and	non‐immune	mechanisms	 associated	with	 a	
modulation	of	gut	microbiota	structure	and	function.
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1  | INTRODUC TION
Infant	colic	(IC)	is	a	functional	gastrointestinal	disorder,	affecting	up	
to	25%	of	infants	in	the	first	3	months	of	life,	with	a	typical	peak	of	
prevalence	at	about	6	weeks	of	age.1	Although	 IC	 is	a	benign	and	
usually	self‐limiting	condition,	it	is	a	source	of	major	distress	for	the	
infant,	parents,	family	and	health‐care	givers.2	It	is	associated	with	
maternal	postpartum	depression,	early	breastfeeding	cessation,	pa‐
rental	guilt	and	frustration,	shaken	baby	syndrome,	multiple	physi‐
cian	visits,	drugs	use,	formula	changing,	long‐term	adverse	outcomes	
such	as	allergy,	behaviour	and	sleep	problems.3,4 The incidence of 
IC	seems	to	be	the	same	between	sexes,	and	no	definitive	correla‐
tion	with	type	of	feeding,	gestational	age,	socioeconomic	status	and	
season	of	the	year	have	been	demonstrated.3,4	Despite	decades	of	
research,	at	present,	the	pathogenesis	of	IC	remains	poorly	under‐
stood	and	is	thought	to	be	multifactorial;	however,	a	growing	body	of	
evidence	suggests	that	alterations	of	gut	microbiota	can	contribute	
to	the	development	of	this	condition.4,5	Distinct	microbial	patterns	
have	been	found	in	IC.	A	lower	diversity	and	stability	of	the	gut	mi‐
crobiota	was	reported	in	subjects	with	IC	during	the	first	2	weeks	of	
life.4,5	These	alterations	suggest	that	a	state	of	gut	dysbiosis	might	
play	 a	 role	 in	 the	 expression	 of	 IC	 symptoms,	modulating	 various	
neural,	endocrine,	immune	and	humoral	signalling	pathways.4‐6
Considering	that	dysbiosis	could	play	a	role	in	the	pathogenesis	
of	IC,	there	is	an	interest	in	gut	microbiota	modulation,	including	the	
use	of	probiotics,	for	the	management	of	IC.	Bifidobacterium anima-
lis	subsp.	lactis,	(BB‐12®)	is	a	well‐known	probiotic,	which	positively	
modulates	the	composition	of	the	intestinal	microbiota	and	the	func‐
tion	of	the	immune	system.7	These	features	likely	make	this	probi‐
otic	 potentially	 useful	 for	 the	 treatment	 of	 IC.	 In	 a	 previous	 trial,	
BB‐12	added	to	a	low	lactose	partially	hydrolysate	formula	contain‐
ing	prebiotics	resulted	effective	in	reducing	the	duration	of	crying	in	
subjects	with	IC.8	To	further	explore	the	potential	efficacy	of	BB‐12	
in	the	treatment	of	IC	we	designed	this	double	blind,	placebo‐con‐
trolled	randomised	trial.
2  | METHODS
This	randomised,	double	blind,	placebo‐controlled	clinical	trial	was	
conducted	 from	 11	 November	 2016	 to	 6	 November	 2017	 at	 the	
Department	of	Translational	Medical	Science—Pediatric	Section	of	
University	of	Naples	“Federico	 II”,	Naples,	 Italy.	The	trial	was	con‐
ducted	in	collaboration	with	a	group	of	family	paediatricians,	operat‐
ing	in	the	city	area	of	Naples,	who	care	for	children	up	to	14	years	
of	age	in	the	Italian	Public	Health	System.	The	family	paediatricians	
were	 asked	 to	 refer	 to	 the	Department	potentially	 eligible	 infants	
and	to	provide	support	to	the	parents	of	those	eventually	enrolled	
by	 the	hospital.	Before	 the	 start	 of	 the	 study,	 all	 investigators	 in‐
volved	in	the	trial	attended	an	investigator	meeting	during	which	the	
study	protocol	was	illustrated	and	discussed,	and	all	definitions	and	
procedures,	including	the	key	factors	in	the	management	of	IC	(such	
as	parental	education,	reassurance	and	empathy)9	were	shared.
The	 study	 protocol,	 the	 subject	 information	 sheet	 and	 the	 in‐
formed	 consent	 form	were	 reviewed	 and	 approved	 by	 the	 ethics	
committee	of	our	institution.
The	study	was	conducted	in	accordance	with	the	Good	Clinical	
Practice	 Standards	 and	 study	 monitoring	 was	 performed	 by	 the	
contract	 research	 organisation	 (CRO),	 blinded	 to	 the	 treatment	
assignment.
The	study	was	registered	in	the	Clinical	Trials	Protocol	Registration	
System	at	ClinicalTrials.gov	with	the	identifier	NCT02988791.
2.1 | Study subjects
Otherwise	 healthy	 exclusively	 breastfed	 infants	 aged	 ≤7	 weeks,	
with	signs	and	symptoms	possibly	related	to	IC	according	to	Rome	
III	Criteria,10	regularly	followed	by	the	family	paediatricians	involved	
in	 the	 trial	were	 considered	eligible	 for	 the	 study.	 Infant	 colic	 (IC)	
criteria	include	all	of	the	following:	paroxysms	of	irritability,	fussing	
or	crying	that	start	and	stop	without	obvious	cause;	episodes	lasting	
3	or	more	hours	per	day	and	occurring	at	least	3	days	per	week	for	at	
least	1	week;	and	no	failure	to	thrive.
The	 exclusion	 criteria	 were	 the	 following:	 age	 ≥7	 weeks,	 birth	
weight	<2500	g,	gestational	age	<37	weeks,	Apgar	score	at	5	min‐
utes	 <7,	 partially	 or	 total	 formula	 feeding,	 stunted	 growth/weight	
loss	 (<100	g/week	from	birth	to	 last	 reported	weight),	neurological	
diseases,	suspected	or	confirmed	food	allergy,	gastroesophageal	re‐
flux	disease,	use	of	probiotics,	prebiotics,	antibiotics	or	gastric	acid‐
ity	 inhibitors	at	any	time	before	enrolment,	 fever	and/or	 infectious	
diseases	at	any	time	before	enrolment,	current	systemic	 infections,	
history	 of	 congenital	 infections,	 chronic	 intestinal	 diseases,	 cystic	
fibrosis	 or	 other	 forms	 of	 primary	 pancreatic	 insufficiency,	 gastro‐
intestinal	 malformations,	 metabolic	 diseases,	 genetic	 diseases	 and	
chromosomal	 abnormalities,	 primary	 or	 secondary	 immunodefi‐
ciency,	insufficient	reliability	or	presence	of	conditions	that	made	the	
patient's	compliance	with	 the	protocol	unlikely	and	participation	 in	
other	studies.
2.2 | Data collection and intervention
At	the	baseline,	after	obtaining	informed	consent	from	the	parents/
tutors	of	each	infant,	the	health	status	of	all	the	study	subjects	was	
carefully	assessed	by	physicians	involved	in	the	trial.	Previous	phar‐
macological	treatment	and	presence	of	infectious	diseases	or	other	
diseases	were	ruled	out	by	means	of	complete	anamnestic	evaluation	
and	 clinical	 examination,	 including	 vital	 signs,	 neurological	 status,	
growth	 status,	 nutritional	 status,	 hydration,	 skin	 evaluation,	 otos‐
copy,	 evaluation	 of	 oral	 cavity,	 respiratory/abdomen/lymphnode	
examination	 and	 genital	 examination.	 Anamnestic,	 demographic,	
anthropometric and clinical data were collected and reported in a 
specific	clinical	chart.
Then,	 infants	were	 required	 to	 follow	a	1‐week	pre‐enrolment	
period.	 If	 after	 this	 period	 the	diagnosis	 of	 IC	was	 confirmed,	 the	
subject	was	randomised	to	one	of	the	following	study	groups:	Group	
1,	parental	 reassurance	and	education	plus	BB‐12	 (Bifidobacterium 
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animalis	subsp.	 lactis	BB‐12®,	DSM	15954,	1	×	109	CFU/daily	dose	
in	oil	maltodextrin	suspension;	Bifidolactis	Infant,	Sofar	SpA);	Group	
2,	parental	reassurance	and	education	plus	placebo	(oil	maltodextrin	
suspension).	Parents	were	requested	to	administer	 to	their	 infants	
six	 drops	 of	 the	 assigned	 study	 product,	 once	 a	 day,	 for	 28	 days	
directly	 in	 the	 mouth,	 preferably	 in	 the	 morning	 before	 feeding.	
Instructions	for	keeping	and	maintaining	the	product	were	also	pro‐
vided	according	 to	 the	manufacturer’s	 indications.	Study	products	
were	 provided	 by	 Sofar	 SpA.	 The	 patient's	 parents,	 investigator	
staff,	persons	performing	the	assessments	and	data	analysts	were	
blinded	 to	 the	 identity	 of	 the	 treatment	 at	 all	 times,	 ie	 allocation,	
intervention,	 laboratory	analysis	and	statistical	analysis.	The	pack‐
aging,	colour,	weight,	smell	and	taste	of	the	investigational	product	
and	of	the	placebo	were	identical	and	thus	ensured	blind	conditions.	
The	 bottles	 containing	 the	 probiotic	 or	 the	 placebo	were	 labelled	
with	consecutive	numbers	without	any	 reference	 to	 the	group	as‐
signment,	which	was	known	only	 to	 the	CRO	and	statistician	who	
generated	the	list	and	to	the	technician	who	prepared	the	packages.	
The	patient's	parents	were	provided	with	a	diary	and	they	were	in‐
structed	on	how	to	complete	it	daily	with	data	concerning	adminis‐
tration	of	daily	dose	of	the	study	product,	number	and	duration	of	
crying	 episodes,	 number	 of	 bowel	movements	 and	 consistency	 of	
baby's	stool	 (according	to	the	Bristol	stool	scale),11	 sleep	duration,	
possible	adverse	events.	Each	study	subject	was	evaluated	by	 the	
hospital	paediatricians	involved	in	the	trial	for	a	total	of	six	visits	over	
a	5‐week	period;	unscheduled	visits	were	performed	 if	necessary.	
At	 each	 visit,	 the	 hospital	 paediatricians	 performed	 a	 full	 clinical	
examination	of	the	infant	and	assessed	and	collected	data	from	the	
diary.	Compliance	was	assessed	by	evaluating	the	diary	provided	by	
the	parent.	In	addition,	parents	were	also	asked	to	return	used	bot‐
tles	to	further	assess	the	compliance	to	assigned	treatment.
The	 possible	 influences	 of	 maternal	 dietary	 factors	 or	 changes	
in	dietary	habits	were	assessed	by	analysing	data	from	7‐days	food	
diary	collected	during	the	week	before	treatment	(V0‐V1).	In	addition,	
possible	changes	in	maternal	diet	were	also	assessed	during	the	last	
week	of	the	study	(V4‐V5).	All	diaries	were	assessed	by	experienced	
dietitians	unaware	of	the	study	aims	and	blinded	to	group	assignment.	
Stool	samples	 (3	g)	were	collected	at	enrolment	before	the	start	of	
therapy,	and	after	4	weeks	of	treatment.	All	samples	were	collected	
from	diapers	in	sterile	plastic	tubes	and	stored	at	−80°C	until	analysis.
At	each	visit,	 the	parents	of	 the	patients	were	asked	to	 report	
any	 side	 effects,	 unexpected	 symptoms	or	 unexpected	events	 re‐
lated	or	not	to	the	treatment	occurred	after	the	last	visit.	All	Adverse	
events	(AEs)	that	occurred	from	the	start	of	the	study	until	the	final	
visit	or	after	30	days	from	the	last	administration	of	study	treatment	
were	 registered.	 For	 each	AE,	 the	nature,	 date	 and	 time	of	onset,	
duration,	 severity	and	correlation	with	 treatment	was	established,	
and	any	changes	in	the	dosage	or	other	treatments	have	been	noted	
in	detail	on	the	case	report	form	(CRF).
Parents	were	 instructed	to	avoid	the	use	pre/pro/synbiotics	or	
any	 anti‐colic	 medications	 during	 the	 study,	 and	 eventual	 use	 of	
other	medications	by	the	study	subjects	was	reported	in	the	diary.	
All	study	procedures	and	assessments	were	performed	as	shown	in	
Figure	1,	panel	a.
F I G U R E  1  Panel	(A).	The	design	of	the	study.	Panel	(B).	The	flow	of	subjects	during	the	phases	of	the	study
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2.3 | Study outcomes
The	 primary	 outcome	 of	 the	 study	was	 the	 proportion	 of	 infants	
with	 a	 treatment	 success	 rate,	 defined	 as	 a	 reduction	of	 ≥50%	of	
mean	daily	crying	duration	after	28	days	of	intervention.
The	 secondary	 outcomes	 were:	 the	 mean	 number	 of	 crying	
episodes;	 sleep	 duration;	 number	 of	 bowel	 movements	 and	 stool	
consistency.	 Study	 groups	were	 also	 compared	 for	 gut	microbiota	
structure,	 faecal	 levels	 of	 human	 beta‐defensin	 2	 (HBD‐2),	 cathe‐
licidin	 (LL‐37),	 secretory	 IgA	 (sIgA),	 calprotectin	 and	 butyrate	 at	
enrolment	and	after	28	days	of	treatment.	Safety	and	the	possible	
occurrence	of	adverse	events	were	also	assessed.
2.4 | Faecal analytical methods’
Human	 beta‐defensin	 2,	 LL‐37	 and	 sIgA	were	measured	 from	 the	
supernatants	of	faecal	homogenates,	using	commercial	kits	as	pre‐
viously	described.12	HBD‐2	was	measured	using	a	HBD‐2	(Human)	
ELISA	 kit	 (Phoenix	 Pharmaceuticals,	 Inc),	 LL‐37	 using	 an	 ELISA	
human	 kit	 (Hycult	 biotechnology)	 and	 sIgA	 using	 indirect	 enzyme	
immunoassay	(Salimetrics	LLC).	The	results	were	expressed	as	ng/g	
for	HBD‐2,	LL‐37	and	as	μg/g	of	supernatant	for	sIgA.
Faecal	 calprotectin	 level	 was	 determined	 using	 a	 commercial	
ELISA	 kit	 (Calprest,	 Eurospital)	 as	 previously	 described,13 and the 
result	was	expressed	as	mg/Kg	of	faeces.
Figure 3 . Assessed for eligibility (n = 80)
Analysed in ITT analysis (n = 40)
Analysed in PP analysis (n = 40)
Lost to follow-up (give reasons) (n = 0)
Discontinued intervention (n = 5: adverse 
event = 1, non compliance of family = 2, difficulty 
in completing diary = 2)
Allocated to BB12 (n = 40) 
Received allocated intervention (n = 40)
Did not receive allocated intervention (n = 0)
Lost to follow-up (give reasons) (n = 0)
Discontinued intervention (n = 3: non
compliance of family = 2, difficulty in completing
diary = 1)
Allocated to placebo (n = 40)
Received allocated intervention (n = 40) 
Did not receive allocated intervention (n = 0)
Analysed in ITT analysis (n = 40) 
Analysed in PP analysis (n = 38)
Allocation
Analysis
Follow-Up
Randomized (n = 80)
Enrollment
Panel (B)
F I G U R E  1   (Continued)
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Faecal	butyrate	level	was	assessed	using	gas	chromatography	as	
previously	described14	and	expressed	as	mM.
Gut	microbiota	structure	was	characterised	using	high‐through‐
put	sequencing	of	16S	rRNA	gene	amplicons.	DNA	extraction,	library	
preparation,	 sequencing	 and	data	 analysis	were	 carried	out	 as	 re‐
cently	described.15	Briefly,	raw	reads	were	joined	using	FLASH16 and 
quality‐filtered	by	Prinseq,17	 trimming	out	bases	with	Phred	 score	
<20	and	shorted	 than	300	bp.	Operational	 taxonomic	units	 (OTU)	
picking	and	taxonomic	assignment	was	carried	out	in	QIIME	v.	1.9.18 
Taxonomic	 identification	of	OTUs	was	achieved	using	Greengenes	
13_5	database	and	OTUs	were	collapsed	at	the	different	taxonomic	
levels.	Alpha‐diversity	indices	(number	of	OTUs,	Shannon	and	Chao1	
indices)	were	computed	in	QIIME.	OTU	table	produced	in	QIIME	was	
imported	in	R	environment	for	further	analyses.	The	16S	rRNA	gene	
sequences	produced	in	this	study	are	available	at	the	Sequence	Read	
Archive	of	the	National	Center	for	Biotechnology	Information,	under	
accession	number	SRP11.
2.5 | Sample size, randomisation and 
statistical analysis
Sample	size	was	calculated	taking	into	account	the	effect	size	esti‐
mated	from	a	previous	trial	on	 IC.19	We	calculated	that	33	 infants	
per	group	were	needed	to	detect	an	absolute	difference	of	35%	of	
the	treatment	success	rate	(from	15%	in	the	placebo	group	to	50%	
in	 the	active	group),	with	a	power	of	0.80	at	an	alpha	 level	of	 .05	
(Pearson's	Chi‐square,	two‐tailed	test).	Assuming	a	dropout	rate	up	
to	20%,	we	calculated	that	40	infants	per	group	had	to	be	enrolled	
into	the	study.	Patients	were	randomised	in	a	1:1	ratio	to	one	of	the	
two	treatment	groups	according	to	a	randomisation	list	generated	by	
a	specific	software	(SAS	for	Windows	release	9.4‐64‐bit).
Descriptive	statistics	are	reported	as	means	and	standard	de‐
viations	for	continuous	variables	and	as	numbers	and	proportions	
for	 dichotomous	 variables.	 Percentages	were	 computed	 consid‐
ering	 subjects	 with	 nonmissing	 information,	 if	 not	 differently	
specified.
The	following	analysis	sets	were	defined:	per	protocol	set	(PP),	all	
randomised	infants	who	completed	the	study	without	any	significant	
protocol	violation;	intention‐to‐treat	set	(ITT),	all	randomised	infants	
who	 received	at	 least	one	dose	of	 study	 treatment;	 safety	 set,	 all	
randomised	 infants	who	received	at	 least	one	dose	of	study	treat‐
ment.	A	subject	who	came	back	for	the	first	visit	after	the	start	of	
treatment	(V2)	was	considered	as	having	received	at	least	one	dose	
of	study	treatment.	The	analysis	of	primary	outcome	was	performed	
on	the	ITT	population,	and	on	the	PP	population	as	supportive.	The	
analyses	 of	 the	 secondary	 outcomes	 were	 performed	 on	 the	 ITT	
population	only.	 The	 safety	 analysis	was	performed	on	 the	 safety	
set	population.
Mean	 daily	 crying	 duration,	 the	 mean	 number	 of	 daily	 crying	
episodes,	 the	mean	 daily	 duration	 of	 sleep	 (in	minutes)	 and	 stool	
frequency	were	described	 for	 each	week	by	means	of	 descriptive	
statistics	 for	 continuous	 data	 and	 were	 calculated	 on	 nonmissing	
TA B L E  1  Main	features	of	the	study	population	at	enrolment
 
Group 1 
BB‐12
Group 2 
Placebo
N. 40 40
Male,	n	(%) 22	(55) 21	(52.5)
Spontaneous	delivery,	n	(%) 15	(37.5) 21	(52.5)
Gestational	age,	mean	week	(SD) 38.5	(1.1) 38.5	(1.2)
Birth	weight,	mean	kg	(SD) 3280.7	
(367.5)
3412	(442.7)
APGAR	score	at	5	min,	mean	(SD) 8.95	(0.4) 8.83	(0.4)
Age,	days,	mean	(SD) 32.9	(5.3) 33.0	(5.0)
Familial	risk	for	allergy,	n	(%) 19	(47.5) 18	(45)
Functional	gastrointestinal	disorders	
in	first‐degree	relatives,	n	(%)
3	(7.5) 7	(17.5)
Exposure	to	passive	smoking,	n	(%) 11	(27.5) 11	(27.5)
F I G U R E  2  Panel	1.	The	results	of	the	main	study	outcome	(ITT	
analysis):	the	rate	of	infants	with	reduction	of	≥50%	of	duration	
of	crying	after	28	days	of	treatment.	Eighty	percent	of	the	BB‐12	
group	and	32.5%	of	the	placebo	group	showed	a	≥50%	reduction	
in	crying	duration	after	28	days	of	treatment.	The	between‐group	
difference	was	significantly	in	favour	of	BB‐12	and	the	asterisk	
indicates	a	significant	difference	(*	=	BB‐12	vs	placebo,	P	<	0.0001).	
Panel	2.	The	mean	number	of	crying	episodes	during	the	week	
before	treatment	(V0‐V1,	blue	bars)	and	during	the	last	week	of	
treatment	(V4‐V5,	light	blue	bars)	in	infants	enrolled	in	the	two	
study	groups.	Values	are	expressed	as	mean	and	SD	and	symbols	
indicate	a	significant	difference	(*	=	BB‐12	V0‐V1	vs	BB‐12	V4‐V5,	
P	<	0.05;	**	=	BB‐12	V4‐V5	vs	Placebo	V4‐V5,	P	<	0.05;	°	=	Placebo	
V0‐V1	vs	Placebo	V4‐V5,	P	<	0.05)
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values;	observations	with	values	equal	to	zero	were	included	in	the	
computation. T	test	was	performed	comparing	the	change	between	
the	two	study	groups	at	each	week.
Stool	consistency	was	evaluated	as	the	number	and	the	propor‐
tion	of	patients	with	at	least	one	stool	sample	of	each	type	per	week	
according	to	the	Bristol	scale.
Safety	 data	 were	 summarised	 by	 treatment	 on	 the	 Safety	 set	
population.	The	incidence	of	Adverse	Events	during	the	study	was	
reported.	 Anthropometric	 data	 were	 summarised	 by	 treatment	
group	by	means	of	descriptive	statistics	for	continuous	variables	at	
V1	and	V5.	Weight	(g)	and	length	(cm)	were	calculated	at	each	visit.	
Changes	from	V0	at	V1	and	V5	were	provided.
Other	secondary	outcomes	were	differences	in	the	faecal	levels	
of	HBD‐2,	LL‐37,	sIgA,	calprotectin	and	butyrate	between	the	two	
groups.	These	values	were	compared	between	the	groups	at	enrol‐
ment	and	after	28‐days	of	treatment	with	an	independent	t	test.
Furthermore,	subjects	were	classified	in	responders	or	nonre‐
sponders	to	treatment	by	using	the	k‐means	clustering	(k	=	2).	The	
best	number	of	clusters	was	defined	using	 the	NbClust	 function	
(NbClust	R	package)	on	a	matrix	containing	variation	(V5‐V1)	of	the	
following	variables:	duration	of	 crying,	LL‐37,	 sIgA,	 faecal	butyr‐
ate,	 calprotectin	 and	 HBD‐2.	 Nonparametric	 Kruskal‐Wallis	 and	
pairwise	Wilcoxon	 tests	were	carried	out	 in	order	 to	 find	differ‐
ences	 in	microbial	 taxa,	butyrate	or	 immunity	peptides	between	
placebo	 and	 BB‐12	 or	 between	 responders	 and	 nonresponders.	
All	p‐values	were	corrected	for	multiple‐comparison	testing	when	
appropriate.20
The	 level	of	 significance	 for	 all	 statistical	 tests	was	 two‐sided,	
P	<	0.05.	All	data	were	collected	in	a	dedicated	database	and	anal‐
ysed	by	a	statistician,	using	SAS®	for	Windows	release	9.4	(64‐bit)	or	
later	(SAS	Institute	Inc)	or	SPSS	for	Windows	(SPSS	Inc,	version	23.0)	
and	GraphPad	Prism	7.0.
3  | RESULTS
The	 flow	of	 the	 subjects	during	 the	 study	 is	 reported	 in	Figure	1,	
panel	b.	Eighty	infants	were	enrolled	and	randomised,	40	per	group;	
eight	 subjects	 did	 not	 complete	 the	 study	 due	 to	 noncompliance	
of	 the	family	 (n	=	3),	difficulty	 in	completing	the	diary	 (n	=	3),	 lost	
to	follow‐up	(n	=	1)	or	adverse	event	(n	=	1).	Seventy‐two	subjects	
completed	the	study:	35	 in	BB‐12	group	and	37	 in	placebo	group.	
All	 infants	 were	 included	 in	 the	 ITT	 and	 safety	 populations	 since	
they	were	randomised	and	received	at	least	one	dose	of	study	treat‐
ment.	Seventy‐eight	infants	were	included	in	the	PP	population	(40	
in	 the	BB‐12	group	and	38	 in	 the	placebo	group)	 since	 they	were	
randomised	and	took	part	in	the	trial	without	any	significant	proto‐
col	violation.	Two	patients	in	the	Placebo	group	(patient	01_12	and	
patient	01_42)	violated	the	protocol	criteria	and	were	excluded	from	
the	PP	population.	Only	one	adverse	event	was	reported	during	the	
study	and	occurred	in	a	patient	treated	with	BB‐12:	the	patient	had	
a	 respiratory	distress	 induced	by	an	upper	 respiratory	 tract	 infec‐
tion,	classified	as	a	serious	adverse	event,	mild	 in	severity	and	 led	
to	permanent	study	treatment	discontinuation.	The	event	resolved	
spontaneously	and	it	was	not	related	to	treatment.
Baseline	 demographic	 and	 anamnestic	 features	 were	 similar	
comparing	 the	 two	 study	 groups	 (Table	 1).	 All	 infants	 were	 from	
families	 of	middle	 socioeconomic	 status	 and	 lived	 in	 urban	 areas.	
No	prior	clinical	or	surgical	events	were	reported.	All	infants	in	the	
probiotic	and	control	were	breast	fed	during	the	entire	study	period.	
None	of	the	infants	received	any	treatments	for	colic	before	study	
entry	and	during	the	trial	period.	Seven‐days	food	diaries	were	avail‐
able	 from	all	mothers	 of	 the	 babies	 included	 in	 the	 study,	 and	no	
dietary	changes	were	observed	during	 the	week	before	 treatment	
(V0‐V1)	and	the	last	week	(V4‐V5)	of	the	study.
In	Figure	2,	panel	1	shows	that	the	BB‐12	group	presented	a	sig‐
nificantly	higher	reduction	in	crying	duration	after	28	days	of	treat‐
ment	compared	 to	 the	placebo	group	 (P	<	0.0001).	Also	 in	 the	PP	
population,	treatment	was	successful	 in	80.0%	of	the	BB‐12	group	
and	in	31.5%	of	the	placebo	group.	Similarly,	the	between‐group	dif‐
ference	was	significantly	lower	in	favour	of	BB‐12	(P	<	0.0001).	The	
rate	 of	 responders	 (decrease	 in	 the	mean	daily	 crying	 duration	 (in	
minutes)	of	≥50%	from	the	baseline	measurement)	was	significantly	
higher	in	the	BB‐12	group	starting	from	the	3rd	week	of	treatment	
(Figure	S1).
The	 mean	 daily	 duration	 of	 crying	 episodes	 was	 consistently	
shorter	in	the	BB‐12	group	at	each	week	and	decreased	from	week	
to	week	in	both	the	ITT	and	PP	population.	Mean	change	from	base‐
line	 (ITT	 population)	 was	 significantly	 greater	 in	 the	 BB‐12	 group	
than	in	the	placebo	group:	−129.9	±	43.7	(range:	−210.0	to	−31.4)	and	
−84.3	±	51.4	(range:	−192.8	to	22.1)	respectively	(P	=	0.0001).	The	
mean	number	of	daily	crying	episodes	was	also	lower	in	the	BB‐12	
group	than	in	the	placebo	group	at	each	week	and	decreased	from	
V1	to	V5.	Mean	change	from	baseline	at	V5	was	significantly	greater	
in	 the	BB‐12	group:	−4.7	±	3.4	 (range:	−16.1	 to	0.4)	 vs	−2.3	±	2.2	
(range:	−7.0	to	1.1)	in	placebo	group	(P	=	0.001)	(Figure	2,	panel	2).
The	sleeping	time	increased	from	baseline,	with	a	mean	change	
at	 V5	 of	 36.5	 ±	 98.8	minutes	 per	 day	 in	 the	BB‐12	 group	 (range:	
−225.7	to	345.0	minutes)	and	47.9	±	108.6	minutes	per	day	(range:	
−265.0	to	225.0	minutes)	in	the	placebo	group.
No	significant	differences	were	observed	comparing	 the	mean	
change	of	daily	stool	frequency	from	baseline	to	V5	in	the	two	study	
groups:	−1.0	±	0.9	(range	−4.0	to	0.2)	in	BB‐12	group	vs	−1.1	±	0.8	
(range:	−2.5	to	1.1)	in	the	placebo	group.
During	the	first	week,	most	patients	had	at	least	one	type	F	stool	
defined	as	“fluffy	pieces	with	ragged	edges,	a	mushy	stool”	(67.5%	in	
the	BB‐12	group	and	85.0%	in	the	placebo	group),	while	during	the	
last	week	most	had	at	 least	one	type	E	stool	defined	as	soft	blobs	
with	clear‐cut	edges,	passed	easily	 (65.0%	 in	the	BB‐12	group	and	
72.5%	in	the	placebo	group).
In	the	Figures	S2‐S5	and	Table	S1	are	reported	the	evolution	week	
by	week	of	the	following	variables:	mean	daily	crying	duration,	mean	
number	of	daily	crying	episodes,	mean	daily	bowel	movements,	stool	
consistency	and	sleep	duration.	A	statistical	difference	 in	 favour	of	
BB‐12	 group	 was	 observed	 in	 mean	 daily	 crying	 duration	 starting	
from	V2	and	in	mean	number	of	daily	crying	episodes	from	V3.
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The	 anthropometric	 parameters	 increased	 within	 the	 normal	
range	from	visit	to	visit	and	they	were	very	similar	in	the	two	groups.	
No	use	of	antibiotics	was	reported.
3.1 | Faecal analytical methods’
Due	to	the	limited	amount	of	faecal	sample	collected	by	the	par‐
ents	we	were	able	to	measure	HBD‐2,	LL‐37,	sIgA,	calprotectin	and	
butyrate	 levels	only	 in	32	subjects	 treated	with	BB‐12	and	 in	30	
infants	who	received	the	placebo.	In	Figure	3	panel	1	shows	fae‐
cal	 levels	 of	HBD‐2	 (panel	 a),	 LL‐37	 (panel	 b),	 sIgA	 (panel	 c),	 bu‐
tyrate	(panel	d)	and	calprotectin	(panel	e)	in	the	two	study	groups	
at	enrolment	and	after	28‐days	of	treatment.	A	significant	increase	
in	HBD‐2,	LL‐37,	sIgA,	calprotectin	and	butyrate	was	observed	in	
the	two	study	groups	as	a	consequence	of	maturation	of	the	 im‐
mune	system	and	gut	microbiome	function.	However,	based	on	the	
variation	(V5‐V1)	of	the	main	study	outcome,	HBD‐2,	LL‐37,	sIgA,	
butyrate	 and	 calprotectin	 faecal	 levels	 we	 identified	 two	 differ‐
ent	clusters	(Figure	3,	panel	2).	Cluster	1	included	10%	of	infants	
enrolled	in	the	BB‐12	group	and	67%	of	infants	enrolled	in	the	pla‐
cebo	group.	Whereas,	Cluster	2	 included	90%	and	33%	of	BB‐12	
and	placebo	subjects	respectively.	We	defined	subjects	in	Cluster	
2	 as	 responders	 to	 the	 treatment,	 since	 they	 showed	 a	 signifi‐
cantly higher reduction of crying and calprotectin compared with 
subjects	in	Cluster	1,	associated	with	a	higher	increase	in	HBD‐2,	
LL‐37,	sIgA	and	butyrate	faecal	levels	(P	<	0.05;	Figure	3,	panel	3).
Due	 to	 the	 limited	 amount	 of	 faecal	 sample	 collected	 by	 the	
parents,	gut	microbiota	structure	was	investigated	only	in	a	subset	
of	 the	 infants	 (23	 subjects	 in	 BB‐12	 group	 and	 10	 in	 the	 placebo	
group).	The	overall	gut	microbiota	structure	remained	unchanged	in	
infants	enrolled	in	the	BB‐12	or	in	the	placebo	group.	No	difference	
in	 alpha‐diversity	 index	was	 observed	 upon	 treatment	 (P	 >	 0.05).	
However,	we	found	a	significant	increase	in	Bifidobacterium only in 
the	responder	infants	(Cluster	2)	treated	with	BB‐12	(P	<	0.05),	and	a	
significant	increase	in	Proteobacteria	in	subjects	enrolled	in	the	pla‐
cebo	group	(P	<	0.05).	Interestingly,	the	variation	of	Bifidobacterium 
induced	by	BB‐12	treatment	correlated	significantly	with	the	reduc‐
tion	of	crying	time	(Figure	4).
4  | DISCUSSION
The	 results	 of	 this	 trial	 suggest	 that	 the	 probiotic	Bifidobacterium 
animalis	 subsp.	 lactis	 BB‐12	 is	 effective	 in	 the	 treatment	 of	 IC.	
Administration	of	BB‐12	at	a	daily	dose	of	1	×	109	CFU	was	associ‐
ated	with	 treatment	 success	 (defined	as	 the	percentage	of	 infants	
who	achieved	a	reduction	in	the	daily	average	crying	time	≥50%)	and	
reduced	crying	time,	with	beneficial	effects	on	sleep	duration	and	on	
stool	frequency	and	consistency.	The	clinical	effect	on	daily	average	
crying	 time	was	already	evident	on	 the	 first	week	of	 treatment	 in	
infants	receiving	BB‐12.	All	these	variables	have	been	considered	as	
clinically	relevant	in	previous	clinical	trials	and	meta‐analyses.21‐23
The	results	are	well	in	line	with	data	of	a	previous	open‐labelled	
trial	 reporting	 that	BB‐12,	 added	 to	 a	 low	 lactose	partially	 hydro‐
lysed	whey	formula,	decreased	the	duration	of	crying	time	in	infants	
with colic.8	Also	the	results	on	stool	pattern	are	well	in	line	with	the	
data	from	previous	trials	showing	that	BB‐12	has	a	beneficial	action	
on	transit	time	and	stool	consistency.24‐27
The	study	has	several	 strengths.	Main	strengths	are	 the	 ran‐
domised,	double	blind,	placebo‐controlled	design,	the	use	of	val‐
idated	 procedure	 for	 IC	 diagnosis	 and	 the	 use	 of	 a	well‐defined	
probiotic	strain	with	a	well	characterised	genome	sequence.7 The 
latter	 is	 relevant	 considering	 the	 surprisingly	 common	 problems	
on	the	quality	of	probiotic	products	used	for	a	wide	range	of	con‐
ditions	recently	 reported	by	the	European	Society	 for	Paediatric	
Gastroenterology	Hepatology	and	Nutrition	(ESPGHAN)	Working	
Group	 for	 Probiotics	 and	 Prebiotics.28 The concomitant evalua‐
tion	of	immunity	and	inflammation	biomarkers,	and	of	gut	micro‐
biota	 structure	 and	 butyrate	 production	 could	 be	 relevant,	 also	
in	 helping	 our	 knowledge	on	 the	 probiotics	 action	 in	 IC.	 Infants	
treated	with	BB‐12	showed	a	higher	increase	of	all	immunity	bio‐
markers	 (HBD‐2,	LL‐37	and	of	sIgA)	compared	to	subjects	 in	 the	
placebo	group,	suggesting	that	this	probiotic	strain	is	able	to	exert	
an	 immunomodulatory	 action	 in	 the	 infant	 gut.	 These	 data	 are	
well	in	line	with	previous	findings	showing	that	BB‐12	modulates	
proliferation	 of	 human	 peripheral	 blood	 mononuclear	 cells	 and	
cytokines	 expression,29,30	with	 protective	 action	 against	 gastro‐
intestinal	 infections	 in	 infants	and	children.	 In	 the	context	of	 IC,	
these	effects	could	be	responsible	for	a	beneficial	shaping	of	gut	
microbiota	structure.	 It	 is	well‐known	that	a	positive	modulation	
of	 HBD‐2,	 LL‐37	 and	 sIgA	 expressions	 into	 the	 intestinal	 lumen	
results	 in	 a	 positive	 influence	 on	 gut	 microbiota	 structure	 and	
butyrate production.15	 These	 effects	 seem	 particularly	 relevant	
in	 IC,	where	dysbiosis	with	 increased	presence	of	Proteobacteria 
and	 decreased	 presence	 of	Bifidobacteria with reduced butyrate 
production	 have	 been	 demonstrated.31,32	 A	 pathogenetic	mech‐
anism	proposed	for	 IC,	 is	the	 increased	intestinal	gas	production	
which	can	be	caused	by	fermentation	of	carbohydrates	and	pro‐
teins	by	Protebacteria.31,32	Similarly,	Bifidobacteria	have	been	asso‐
ciated	with	decreased	amounts	of	crying.33	We	found	that	BB‐12	
is	able	to	counteract	all	these	events,	inhibiting	the	Proteobacteria 
increase	 and	 facilitating	 the	 Bifidobacteria	 increase	 and	 butyr‐
ate	production	 in	 infant	with	colic.	These	effects	were	observed	
in	 the	 vast	majority	 but	 not	 in	 all	 infants	 enrolled	 in	 the	 BB‐12	
group,	 supporting	 the	 hypothesis	 that	 other	 factors	 could	 influ‐
ence	these	effects.	The	beneficial	role	of	Bifidobacteria	in	IC	was	
also	demonstrated	by	 the	 significant	 correlation	with	 the	 reduc‐
tion	of	crying	time	observed	in	this	trial.	Bifidobacteria are not able 
to	produce	butyrate,	but	through	cross‐feeding	other	commensal	
bacteria,	 they	 can	 increase	 butyrate	 levels	 potential	 influencing	
many	aspects	of	gut	physiology.34	Butyrate	is	a	major	gut	microbi‐
ota	metabolite	able	to	exert	a	wide	range	of	beneficial	actions	at	
intestinal	and	extra‐intestinal	level.34	Butyrate	modulates	intesti‐
nal	transit	time,	visceral	and	central	pain	perception	and	gut‐brain	
axis,	and	exerts	a	potent	anti‐inflammatory	action.35‐46 The faecal 
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F I G U R E  3  Panel	1.	The	values	
of	innate	and	acquired	immunity	
biomarkers,	calprotectin	and	
butyrate	faecal	levels	at	baseline	
during	the	week	before	treatment	
(V0‐V1,	blue	bars)	and	during	the	
last	week	of	treatment	(V4‐V5,	
light	blue	bars)	in	the	two	study	
groups.	Panel	A:	human	β‐defensin	
2;	panel	B:	cathelecidin	(LL‐37);	
panel	C:	secretory	IgA;	panel	D:	
butyrate; panel E: calprotectin. 
Values	are	expressed	as	mean	
and	SD	and	asterisks	indicate	a	
significant	difference	(*	=	P	<	0.05).	
Panel	2.	The	k‐means	clustering	
(k	=	2)	of	subjects	based	on	the	
variation	(V5‐V1)	of	the	crying	
time,	beta‐defensin	2,	LL‐37,	sIgA,	
butyrate,	faecal	calprotectin	levels	
after	28	days	of	treatment.	Cluster	
1	(yellow	dot)	included	10%	of	
infants	enrolled	in	the	BB‐12	group	
and	67%	of	infants	enrolled	in	the	
placebo	group.	Whereas,	Cluster	2	
(blue	dot)	included	90%	and	33%	
of	BB‐12	and	placebo	subjects	
respectively.	Panel	3.	The	boxplots	
showing	the	variation	(V5‐V1)	
of	crying	time	(in	minutes),	beta‐
defensin	2,	LL‐37,	sIgA,	butyrate	
and	faecal	calprotectin	levels	in	
subjects	classified	in	Cluster	1	or	2.	
Boxes	represent	the	interquartile	
range	(IQR)	between	the	first	and	
third	quartiles,	and	the	line	inside	
represents	the	median	(2nd	quartile).	
Whiskers	denote	the	lowest	and	
the	highest	values	within	1.5	×	IQR	
from	the	first	and	third	quartiles	
respectively.	Asterisks	indicate	a	
significant	difference	as	obtained	by	
pairwise	Wilcoxon	test	(P	<	0.05)
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calprotectin	features	have	been	explored	by	only	few	authors	with	
conflicting	results.47,48	We	found	a	different	modulation	of	calpro‐
tectin	in	responder	infants	to	BB‐12	intervention,	suggesting	that	
calprotectin could be involved in the modulation of the gut inflam‐
matory	state	elicited	by	this	probiotic.
Finally,	 it	 is	well‐known	that	butyrate	modulates	HBD‐2,	LL‐37	
and	 sIgA	 production,15	 supporting	 the	 hypothesis	 of	multiple	 and	
connected	actions	elicited	by	BB‐12	in	IC.
The	main	limitations	of	this	trial	are	related	to	the	relatively	small	
number	of	observations,	the	inclusion	of	subjects	up	to	7	weeks	and	
the	exclusion	of	 formula	 feeding	 infants.	All	 these	points	 limit	 the	
generalisability	of	this	study,	and	future	trials	may	help	in	better	elu‐
cidating	the	action	of	BB‐12	in	infant	colic	and	gut	homeostasis.
In	conclusion,	our	study	provides	compelling	evidences	for	 the	
efficacy of Bifidobacterium animalis	subsp.	lactis	BB‐12	in	the	treat‐
ment	of	IC.	These	evidences	further	support	the	important	role	of	
gut	microbiota	as	target	of	intervention	against	IC.	It	is	relevant	to	
underline	that	this	trial	studied	a	specific	well‐characterised	probi‐
otic	strain,	and	that	these	findings	cannot	be	extrapolated	for	other	
probiotic	strains.
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